Figure 3.

Characteristics of anti-HER2-targeted therapy combined with anti PD-1/PD-L1 immunotherapy. The activity of HER2 receptors is inhibited by anti-HER2-targeting drugs, which enhances the ability of immune cells to attack tumors. At the same time, anti-PD-1/PD-L1 immunotherapy can promote immune cell activity and alleviate tumor cell resistance to HER2-targeting drugs, exerting a synergistic antitumor effect. TCR, T-cell receptor; MHC, major histocompatibility complex; FcR, Fc Receptor; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; NK, natural killer; HER, human epidermal growth factor receptor; ADCC, antibody-dependent cell-mediated cytotoxicity.